Send me a link:

*Text messaging rates may apply.

 Dow Down0.72% Nasdaq Down0.50%

Epizyme, Inc. (EPZM)

33.14 Down 0.33(0.99%) Jul 25, 3:59PM EDT
ProfileGet Profile for:
Epizyme, Inc.
400 Technology Square
4th Floor
Cambridge, MA 02139
United States - Map
Phone: 617-229-5872
Fax: 617-349-0707

Index Membership:N/A
Full Time Employees:74

Business Summary 

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Epizyme, Inc.

Corporate Governance 
Epizyme, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Robert J. Gould Ph.D., 59
Chief Exec. Officer, Sec. and Director
Mr. Jason P. Rhodes , 44
Pres, Chief Financial Officer, Principal Accounting Officer and Treasurer
Mr. Robert A. Copeland Ph.D., 57
Chief Scientific Officer and Exec. VP
Dr. Eric E. Hedrick M.D., 49
Chief Medical Officer
Dr. H. Robert Horvitz Ph.D.,
Co-Founder and Chairman of the Scientific Advisory Board
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders